Mylan completed the merger with Pfizer's off-patent medicines unit.

Mylan, a global generic and specialty pharmaceuticals company, completed the merger with Pfizer's off-patent medicines unit. Under the terms of the agreement, which is structured as an all-stock, each Mylan share was converted into one share of the new company. Pfizer shareholders own 57% of the combined new company, and Mylan shareholders own 43%. "We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitude to our Upjohn colleagues for their dedication in helping us achieve this milestone. Looking ahead at the new Pfizer, we believe our pipeline has never been stronger, and we are energized and inspired to continue developing breakthrough treatments and delivering innovative, life-changing medicines to patients around the world," Albert Bourla, Pfizer Chairman and CEO. 30/10/2020: Mylan and Pfizer recieves FTC clearance in the proposed combination of Mylan and Upjohn.